Medtronic spin-out Inspire CE marks first neurostim-based sleep apnoea therapy
This article was originally published in Clinica
Executive Summary
Inspire Medical Systems has CE marked its Inspire upper airway stimulation (UAS) therapy, making it the first neurostimulation-based treatment for obstructive sleep apnoea (OSA) to be approved for sale in Europe. The firm intends to begin "initial European market development activities" in late 2011.